302
Participants
Start Date
February 29, 2012
Primary Completion Date
June 30, 2013
Study Completion Date
September 18, 2013
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.
"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment."
Tobramycin inhalation solution using a PARI LC® Plus nebulizer.
"300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.~* Nebulization time is approximately 20 minutes for each administration.~* Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment"
Vienna
Brussels
Ghent
Leuven
Pleven
Plovdiv
Sofia
Varna
Hamilton
Halifax
Vancouver
Copenhagen
Bron
Lille
Montpellier
Nancy
Paris
Pierre-Bénite
Rouen
Berlin
Essen
Hamburg
Hanover
Kiel
München
Athens
Marousi
Budapest
Debrecen
Szeged
Dublin
Ancona
Brescia
Catania
Genova
Milan
Parma
Roma
Verona
Utrecht
Gdansk
Lodz
Lublin
Poznan
Rabka-Zdrój
Rzeszów
Warsaw
New Belgrade
Banská Bystrica
Bratislava
Košice
Barcelona
Madrid
Valencia
Gothenburg
Birmingham
Glasgow
Leeds
Liverpool
London
Nottingham
Penarth
Insmed Incorporated
INDUSTRY